Covid19 Vaccine Clinical Trial
Official title:
A Parallel Group, Prospective, Randomized, Double-blind, Two-arm, Single-center Study to Evaluate the Immunogenicity, Safety, and Tolerability of mRNA-1273 in Heterologous Prime-Boost With MVC-COV1901 in Adult Volunteers of 20 to 70 Years
The primary objective of the study is to evaluable the safety and to demonstrate the immunogenicity of heterologous prime-boost (mRNA-1273, MVC-COV1901), compared to homologous prime-boost (mRNA-1273), with an interval of 8-12 weeks, This study also assesses the safety and tolerability of the study intervention and explores the immunogenicity by the antigen-specific immunoglobulin, the immunogenicity against the VoCs, the antigen specific cellular immune response, as well as the potential efficacy of study intervention in preventing COVID-19.
This is a parallel group, prospective, randomized, double-blind, two-arm, single-center study to be conducted in approximately 220 healthy participants aged 20 to 70 years who are generally healthy or with stable pre-existing health condition. The participants should previously have their first dose of mRNA-1273. The participants, investigators, and the site personnel will be blinded to the study intervention assignment until all the participants complete their Day 29. Preparation and administration of study intervention will be performed by authorized unblinded site personnel who do not participate in the evaluation of the participants. Eligible participants will be randomized to receive either mRNA-1273 or MVC-COV1901 vaccine at a 1:1 ratio. Randomization of participants will be stratified by the interval apart from their first dose of mRNA-1273 (< 10 weeks or ≥ 10 weeks). The study consists of 6 on-site visits: Day -28 to Day 1, Visit 1 (Screening) Day 1, Visit 2 (study intervention) Day 15 ± 3 days, Visit 3 Day 29 ± 3 days, Visit 4 Day 91 ± 14 days, Visit 5 Day 181 ± 14 days, Visit 6 Unscheduled visit(s) may be arranged when deemed necessary by the investigator. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05011526 -
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults
|
Phase 3 | |
| Completed |
NCT04822025 -
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults
|
Phase 2 | |
| Completed |
NCT04818892 -
Immunogenicity of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease
|
||
| Completed |
NCT04951388 -
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents
|
Phase 2 | |
| Not yet recruiting |
NCT04730895 -
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.
|
Phase 1/Phase 2 | |
| Completed |
NCT05048849 -
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study
|
Phase 2 | |
| Completed |
NCT04765436 -
PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64
|
Phase 1 | |
| Active, not recruiting |
NCT04760704 -
Covid-19 Vaccine Response in Elderly Subjects
|
||
| Completed |
NCT04695652 -
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult
|
Phase 2 | |
| Withdrawn |
NCT05029245 -
IntraDermal Versus Intramuscular Comirnaty® Efficacy Study
|
Phase 3 | |
| Completed |
NCT05038618 -
A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study
|
Phase 2 | |
| Completed |
NCT05175742 -
PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.
|
Phase 2 | |
| Recruiting |
NCT04834869 -
COVID-19 Vaccines Safety Tracking (CoVaST)
|